Analyst Expectations for CymaBay Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for CymaBay Therapeutics (NASDAQ:CBAY) within the last quarter, with 10 out of 11 analysts offering a bullish stance. The average 12-month price target for the company has increased by 25.12% from the previous average, now standing at $17.73.
August 31, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a bullish stance towards CymaBay Therapeutics, which could potentially boost investor confidence and positively impact the stock price.
Analyst ratings often influence investor sentiment and can impact stock prices. The overwhelmingly bullish stance towards CymaBay Therapeutics and the increased price target suggest a positive outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100